ArticleAmerican journal of cancer research2025

Comparing health insurance-reimbursed lenvatinib and self-paid atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.

Yuan-Hung Kuo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.